
Opinion|Videos|March 27, 2025
First-Line Therapy for Advanced HCC: The Role of TKIs and ICIs
Author(s)Richard S. Finn, MD, Amit Singal, MD
Panelists discuss how current first-line systemic therapies for advanced hepatocellular carcinoma (HCC) include atezolizumab + bevacizumab and durvalumab + tremelimumab, replacing tyrosine kinase inhibitors (TKIs) like sorafenib and lenvatinib. Emerging combinations with anti–PD-L1 agents enhance efficacy. TKI + immune checkpoint inhibitor (ICI) combinations offer synergistic benefits but pose toxicity, cost, and biomarker challenges.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Briefly discuss current approved first-line systemic therapies for advanced HCC.
- How are emerging combination strategies, particularly with anti–PD-L1 agents, reshaping the first-line treatment landscape?
- What are the potential advantages of TKI + ICI combinations compared with TKI monotherapy?
- Please also discuss potential challenges.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
KRAS-Mutant Lung Cancer: Unmet Needs Persist Beyond G12C, Expert Says
2
FDA Advisory Committee to Review Galleri MCED Test's PMA Application
3
Adding Ibrutinib to Liso-Cel Drives Deep Remissions in R/R CLL/SLL
4
AI Model Predicts Late Distant Recurrence Risk in HR-Positive Breast Cancer
5











































